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MARS: A Sense of 
Perspective and an 
Inconvenient Truth
bring up several salient points that war-
rant further discussion. The first issue 
raised is that with developing technol-
ogy and in certain instances acute grade 
III esophagitis may be the dose-limiting 
factor for thoracic tumors. We agree 
that every clinical case is unique and 
the dose-limiting organ can be depen-
dent on tumor location, tumor size, 
and treatment technique and design. 
However, the risk of radiation pneu-
monitis is still considered by many 
groups to be one of the most critical 
limiting factors in increasing doses to 
lung tumors.2 The aim of our work was 
to illustrate the concept of personaliz-
ing prescription doses, based on avail-
able single nucleotide polymorphism 
and radiation pneumonitis data. We 
believe the idea of personalized toxicity 
estimates can and should be expanded 
to other thoracic organs at risk as data 
become available and model accuracy 
improves.
For some of our simulations we 
noted that our model indicated lower 
tumor doses (implying dose de-esca-
lation) than what was clinically deliv-
ered for a cohort of patients to keep 
the clinical severe pneumonitis at an 
acceptable level. We should underline 
that we are not suggesting the idea of 
dose de-escalation but rather this result 
is a product of our study design. For a 
percentage of our patient cohort, the 
simulation suggested dose de-escala-
tion because at the time of treatment 
the physician made a clinical judg-
ment to exceed constraints that we set 
for the nonlung organs (esophagus, 
spinal cord, and heart). When those 
patients were excluded from the study, 
the changes in prescription dose were 
approximately zero, indicating that the 
positive and negative changes in dose 
cancelled out; which can be expected 
when the same data set is used for gen-
erating the model and performing the 
simulation. With the above in mind, 
our results still show some patients 
for whom the model suggested a dose 
de-escalation to control the incidence 
of pneumonitis. For those patients, we 
completely agree with Troost et al. in 
that tumor control is of primary impor-
tance and “more tailored solutions are 
feasible.” Instead of dose de-escalation 
we cite some examples of redesigning 
the beam arrangement or replanning 
the patient with different treatment 
modalities (protons versus photons 
for example).1 The work done by Van 
Baardwijk et al.3 is also an excellent 
example of how the dose can be esca-
lated while keeping toxicity rates at an 
acceptable level. There are many ways 
to adapt a treatment plan based on a 
patient’s personalized toxicity risk, and 
we feel it is important to characterize 
each step individually before a com-
plete paradigm of treatment personal-
ization is clinically implemented. The 
aim of our work was to characterize 
one step of the process rather than pro-
pose a complete solution.
The virtual trial presented in our 
work is a proof of principle study and 
should be placed in proper perspective. 
The personalized toxicity work is one 
step in a multistep complicated pro-
cess. The model will not replace tumor 
control consideration, the clinical judg-
ment of the physician, or vary patient 
and clinical scenarios. More work will 
be needed to determine how the results 
from personalized toxicity estimates 
can be properly incorporated into the 
treatment process.
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To the Editor:
It is important to correct the 
record concerning the Mesothelioma 
and Radical Surgery (MARS) trial1 
referred to in the November issue of 
the Journal of Thoracic Oncology by 
Hedi Kindler2 and Valerie Rusch et al.3 
The points they raise here have been 
rehearsed at conferences around the 
world in the course of discussion of the 
place of extrapleural pneumonectomy 
(EPP) for malignant pleural mesothe-
lioma. They merit examination and, in 
some instances, robust rebuttal.
MARS reported just 50 random-
ized patients, a small number.1,4 The 
Clinical Trials Awards and Advisory 
Committee (CTAAC) of Cancer 
Research, United Kingdom funded 
a 50-patient study to test feasibil-
ity, aware of the potential difficulty of 
recruiting and randomizing patients. 
At that time the sample size estimated 
to ensure that a randomized study 
would be 80% sure to detect a sur-
vival advantage attributable to EPP 
was 670 patients. This power calcula-
tion was based on the certificated time 
to death of 426 unoperated patients 
surgically diagnosed with malignant 
pleural mesothelioma compared with 
reported survival of patients who had 
EPP as part of completed multimodal-
ity therapy. Had MARS proceeded to 
the larger study, the 50 patients would 
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have been included in that analysis. In 
the event 50 patients were sufficient to 
raise a serious concern that the surgi-
cal component of multimodal treatment 
might in fact shorten life, and reduce its 
quality, amply illustrating the cogency 
of Lilford’s maxim “some unbiased evi-
dence is clearly better than none.”
To say that MARS had “an opera-
tive mortality substantially higher than 
that of any other contemporary series” is 
disingenuous. If there are zero, one, two, 
or three events in a series of 25, the per-
centage rates are 0%, 4%, 8%, and 12% 
and the exact confidence limits around 
these overlap widely. If there had been no 
perioperative deaths in MARS it would 
have been just as inappropriate to claim 
mortality to be substantially lower than 
in other reports (the upper 95% confi-
dence limit of 0 of 25 is 13.7%). The 
plain fact is that EPP mortality in MARS 
(2 of 19; 10.5%; exact 95% confidence 
limits 1.3%–33.1%) lies within the 
range of reported data: in a systematic 
review of 34 studies, including 2320 
patients, 30-day mortality ranged from 
0% to 11.8%.
MARS outcomes for patients 
allocated to surgery have external 
validity. The objective of EPP is not 
survival to 30 days (or one would not 
remove a lung, the pericardium, and the 
diaphragm) but rather better long-term 
survival, and in this regard MARS EPP 
results are entirely in line with major 
series in the literature. EPP cohorts of 
100, 385, 121, and 208 patients, pub-
lished from 2007 to 2009, reported 
median survival times of 10, 12, 13, and 
14 months, respectively.4 The median 
survival of patients in the EPP arm of 
MARS was 14.4 months from random-
ization. The important, and perhaps for 
some inconvenient, finding was that 
among patients considered suitable for 
EPP but randomized to not have surgery, 
the median survival was 19.5 months, 
better than among the EPP patients in 
MARS and better than among the surgi-
cal series cited above (Fig. 1).
The MARS results have broad 
clinical face validity. The results came 
as no great surprise to all except a small 
number of proponents of EPP. The effort 
in providing data that shows that EPP is 
not a proven treatment earned the 2012 
Lifetime Achievement Award of the 
British Thoracic Oncology Group.
The feasibility of performing 
randomized trials was demonstrated. 
MARS took 3 years (2005–2008) to 
register 112 patients, by signed con-
sent, into the first phase of the study. 
Only 18 withdrew of their own volition 
and, after clinical exclusions, 57 gave 
further signed consent to be random-
ized.1,4 The EORTC 08031 nonrandom-
ized observational study took 2 years 
(2005–2007) to recruit 59 patients and 
arguably the fair comparison would be 
with the accrual rate of 112 patients into 
the nonrandomized phase of MARS.5 
Rather than seeking to fault MARS it 
is surely time to put effort into finding 
high-quality evidence, for example, 
concerning the effectiveness of lung-
sparing surgery on quality of life, so 
that we can provide evidence-based 
advice to patients.
FIGURE 1.  Median survival of patients with and without EPP.
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Drs. Treasure, Utley, and O’Byrne 
write to correct what they consider to be 
misperceptions about the Mesothelioma 
and Radical Surgery (MARS) trial. 
Significant concerns about the methodol-
ogy used in this trial have already been 
reported by an international group of 
mesothelioma investigators1 and do not 
need to be reiterated here. A major con-
cern was that a trial, originally designed to 
accrue 50 patients with malignant pleural 
mesothelioma (MPM) to test the feasibil-
ity of randomizing between extrapleural 
pneumonectomy (EPP) versus no surgery, 
was reported as a definitive phase III trial 
showing no survival benefit for EPP. This 
is a fundamental violation of the principles 
of clinical trial analysis and reporting.
The focus of the article published 
in the November issue of the Journal of 
Thoracic Oncology2 and of the accompa-
nying editorial3 was the successful effort 
by the International Association for the 
